References
- Carrington CB, Addington WW, Goff AM, Madoff IM, Marks A, Schwaber JR, et al. Chronic eosinophilic pneumonia. N Engl J Med 1969;280:787–798.
- Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Medicine (Baltimore) 1998;77:299–312.
- Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore) 1988;67:154–162.
- Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994;150:1423–1438.
- Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005;60:1004–1013.
- Hueto-Perez-de-Heredia JJ, Dominguez-del-Valle FJ, Garcia E, Gomez ML, Gallego J. Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome. Eur Respir J 1994;7:1006–1008.
- Bennett AN, Wong M, Zain A, Panayi G, Kirkham B. Adalimumab-induced asthma. Rheumatology (Oxford) 2005;44:1199–1200.
- Berry M, Brightling C, Pavord I, Wardlaw AJ. TNF-alpha in asthma. Curr Opin Pharmacol 2007;7:279–282.
- Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B. Asthma unmasked with tumor necrosis factor-α-blocking drugs. Chest 2011;140:1068–1071.
- Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract 2014;2:671–680; quiz 681.
- Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41:256–264.
- Mărgineanu I, Crişan R, Mihăescu T. Asthma-like symptoms in a patient with rheumatoid arthritis and Adalimumab treatment. Pneumologia 2015;64(4):28–30.
- Stoll ML, Solomon DH, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, Shadick NA. TNFα inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma. J Clin Rheumatol 2009;15(4):198–200.
- Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med 2009;103(5):661–9.
- Adamson R, Yazici Y, Katz ES, Greisman SG, Steiger D. Fatal acute necrotizing eosinophilic myocarditis temporally related to use of adalimumab in a patient with relapsing polychondritis. J Clin Rheumatol 2013;19(7):386–9.
- Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol 1977;128:1–13.
- Fox B, Seed WA. Chronic eosinophilic pneumonia. Thorax 1980;35:570–580.
- Terán LM, Ledesma-Soto Y, Krengel S, Lezcano-Meza D. The role of eotaxins in bronchial asthma and nasal polyposis. Gac Med Mex 2006;142:139–144.
- Beninati W, Derdak S, Dixon PF, Grider DJ, Strollo DC, Hensley RE, et al. Pulmonary eosinophils express HLA-DR in chronic eosinophilic pneumonia. J Allergy Clin Immunol 1993;92:442–449.
- Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts M. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001;32:114s–118s.
- Naughton M, Fahy J, FitzGerald MX. Chronic eosinophilic pneumonia: A long-term follow-up of 12 patients. Chest 1993;103:162–165.
- Kaya H, Gümüş S, Uçar E, Aydoğan M, Muşabak U, Tozkoparan E, et al. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest 2012;142:513–516.
- Lam W, Ramsey A. Novel use of anti IL-5 Therapy, Mepalizumab, in chronic eosinophilic pneumonia (poster presentation P156 at ACAAI Nov. 2016). Ann Allergy Asthma and Immun 17:S68.